Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Daniel Pollyea

Leukemia · CU Anschutz Medical Campus

View

Dr. Jessica Altman

Leukemia · Northwestern Medicine

View

Dr. Shella Saint Fleur-Lominy

Leukemia · UMSOM

View

Dr. Azra Raza

Leukemia · CUIMC

View

Dr. Molly Imgruet

Leukemia · Stanford

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    NDDr. Naval Daver
    Leading Voice

    Dr. Naval Daver

    Hematology & Oncology · Leukemia
    The University of Texas MD Anderson Cancer Center
    naval

    Research

    Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia

    2025

    Via Bone Marrow Transplantation

    Research

    The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

    2025

    Via Blood

    Research

    Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

    2025

    Via Blood Cancer Journal

    Research

    The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma

    2025

    Via Blood Advances

    Research

    Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome

    2025

    Via Leukemia Research

    Research

    Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia

    2025

    Via Blood Cancer Journal

    Research

    A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm

    2025

    Via Leukemia & Lymphoma

    Research

    Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias

    2025

    Via Clinical Cancer Research

    Research

    BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

    2025

    Via Blood

    Research

    Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements

    2025

    Via Leukemia

    Research

    Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia

    2025

    Via EJHaem

    Research

    A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

    2025

    Via American Journal of Hematology

    Research

    Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial

    2025

    Via The Lancet Haematology

    Research

    Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML

    2025

    Via Journal of Clinical Oncology

    Research

    Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

    2025

    Via Nature Genetics